Dr. Lal PathLabs reports FY26 results, ₹4 final dividend, 100% Shahbazkers Diagnostic stake
Dr Lal Pathlabs · Healthcare Services
Key highlights
- FY26 profit for the year: consolidated INR 5,098 million; standalone INR 5,082 million.
- Board recommended final dividend of INR 4 per equity share, subject to AGM approval; record date June 26, 2026.
- Filing discloses acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited, to become wholly owned subsidiary.
Why it's rated notable: the year-on-year change is 15% (10% to 20% for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Dividend Updates
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Dr Lal Pathlabs
- Acquisition / mergerNotableDr. Lal PathLabs completes acquisition of stake in SN Genelab Private Limited
- Acquisition / mergerNotableDr Lal PathLabs completes acquisition of 80% stake in Sunshine Healthcare Limited, Ghana
- Acquisition / mergerNotableDr. Lal PathLabs approves Q1 FY2026-27 results, INR 5 interim dividend and stock options
- Acquisition / mergerNotableDr Lal PathLabs reports Q1 FY27 revenue of ₹798 Cr, up 19.1%
- Acquisition / mergerNotableDr. Lal PathLabs Q1 FY27 results, ₹5 interim dividend, Ghana and Neuome stake deals
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.